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AbsTrACT
background Mycoplasma genitalium is increasingly 
seen as an emerging sexually transmitted pathogen, 
and has been likened to Chlamydia trachomatis, but its 
natural history is poorly understood. The objectives of 
this systematic review were to determine M. genitalium 
incidence, persistence, concordance between sexual 
partners and the risk of pelvic inflammatory disease 
(PID).
Methods We searched Medline, EMBASE, LILACS, 
IndMed and African Index Medicus from 1 January 1981 
until 17 March 2018. Two independent researchers 
screened studies for inclusion and extracted data. We 
examined results in forest plots, assessed heterogeneity 
and conducted meta-analysis where appropriate. Risk of 
bias was assessed for all studies.
results We screened 4634 records and included 18 
studies; six (4201 women) reported on incidence, five 
(636 women) on persistence, 10 (1346 women and 
men) on concordance and three (5139 women) on 
PID. Incidence in women in two very highly developed 
countries was 1.07 per 100 person-years (95% CI 0.61 
to 1.53, I2 0%). Median persistence of M. genitalium 
was estimated from one to three months in four studies 
but 15 months in one study. In 10 studies measuring 
M. genitalium infection status in couples, 39%–50% of 
male or female sexual partners of infected participants 
also had M. genitalium detected. In prospective studies, 
PID incidence was higher in women with M. genitalium 
than those without (risk ratio 1.73, 95% CI 0.92 to 3.28, 
I2 0%, two studies).
Discussion Incidence of M. genitalium in very highly 
developed countries is similar to that for C. trachomatis, 
but concordance might be lower. Taken together with 
other evidence about age distribution and antimicrobial 
resistance in the two infections, M. genitalium is not 
the new chlamydia. Synthesised data about prevalence, 
incidence and persistence of M. genitalium infection 
are inconsistent. These findings can be used for 
mathematical modelling to investigate the dynamics of 
M. genitalium.
registration numbers CRD42015020420, 
CRD42015020405
InTroDuCTIon
Mycoplasma genitalium is increasingly seen as an 
emerging sexually transmitted pathogen.1–4 M. 
genitalium is a cause of non-gonococcal urethritis1 
and cervicitis,3 and associations with pelvic inflam-
matory disease (PID), other reproductive tract 
complications in women and adverse pregnancy 
outcomes have been found.3 M. genitalium has thus 
been called the ‘new chlamydia’.5 In a previous 
systematic review, we found a prevalence of M. 
genitalium of approximately 1% in sexually active 
heterosexuals in the general population, which is 
similar to that reported for Chlamydia trachomatis 
aged 16–44 years.6 In sex workers, men who have 
sex with men (MSM) and clinic-based populations 
prevalence was higher and more variable.7 The 
increasing availability of nucleic acid amplification 
tests (NAAT) that detect M. genitalium has resulted 
in debate about the need for widespread testing of 
asymptomatic populations.8–10 But increased testing 
and treatment are likely to increase the already high 
proportion of antimicrobial resistant M. genitalium 
since resistance to macrolides often emerges during 
treatment.11 12
Mathematical modelling could help to under-
stand the balance of benefits and harms that wide-
spread testing and treatment interventions bring.9 
To develop mathematical models, we need robust 
estimates from clinical and epidemiological studies 
about key variables that determine the spread 
of infection in a population13 and progression to 
complications.9 These variables include the inci-
dence of infection; persistence of untreated infec-
tion, which can be used to estimate the duration 
of infectiousness;14 concordant M. genitalium 
status between sexual partners, which can be used 
to derive the transmission probability;15 16 and the 
probability that M. genitalium in the lower genital 
tract ascends to cause PID, which can result in 
tubal factor infertility and ectopic pregnancy.17 In 
the first published model of M. genitalium trans-
mission and the impact of screening, the authors 
noted the uncertainty about the values used for 
parameters describing the natural history of infec-
tion and progression to PID.9 The objectives of this 
study were to systematically review the research 
literature to estimate the incidence of M. genitalium 
infection, persistence of untreated M. genitalium, 
concordance of M. genitalium detection and the 
risk of developing PID.
MeThoDs
This systematic review is one of two linked reviews 
that used a single search strategy and are described 
in two protocols.18 19 A review of the prevalence of 
M. genitalium has been published.7 We report our 
findings according to the Preferred Reporting Items 
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for Systematic Reviews and Meta-Analyses (PRISMA, online 
supplementary file 1).20
eligibility criteria
We included studies of M. genitalium detected by NAAT. Study 
populations were women and men older than 13 years in any 
country. Eligible study designs were as follows: for incidence of 
M. genitalium, cohort studies with participants who were unin-
fected at baseline; for persistence, cohort studies that followed 
people with untreated M. genitalium infection; for concordance, 
cross-sectional studies which enrolled couples or sexual partners 
of index cases, excluding studies in which the infection status of 
a sexual partner was based on self-report; for incidence of PID, 
cohort or nested case–control studies that compared women with 
and without M. genitalium, excluding cross-sectional studies and 
case–control studies in which it could not be established that M. 
genitalium infection preceded a diagnosis of PID.
Information sources and search strategy
We searched Medline and EMBASE databases for publications 
in any language from 1 January 1981 until 12 July 2016 and 
updated the search to 17 March 2018. We used thesaurus head-
ings and free-text terms that combined Mycoplasma or Myco-
plasma genitalium with genital tract complications (online 
supplementary file 2, online supplementary text S1–3). We also 
searched the African Index Medicus, IndMED and LILACS, 
using the term Mycoplasma genitalium. Records were managed 
using EndNote (V.X8.1; Clarivate Analytics, Philadelphia, Penn-
sylvania, USA).
study selection
Abstracts published before 1 January 1991 were excluded. Two 
reviewers (MC, LB) assessed study eligibility independently, 
using a pre-piloted screening form. We resolved differences by 
discussion or adjudication by a third reviewer (NL).
Data collection
Two reviewers (MC, LB, DE-G, HA) extracted data inde-
pendently. Differences were resolved by discussion or adju-
dication. We extracted data using a standardised, piloted data 
extraction form in a Research Electronic Data Capture database 
(REDCap; Vanderbilt University, Nashville, Tennessee, USA). 
For each study, we extracted data about study characteristics, 
methods and results. For studies reporting persistence of M. 
genitalium only in graphs, we used Plot Digitizer software21 to 
record numerical data. We labelled studies with the country in 
which the data were collected and added consecutive numbers 
for studies subsequently identified from the same country. Studies 
reported in the linked systematic review of M. genitalium preva-
lence have the same study identifier (online supplementary table 
S1).7 We contacted authors to clarify details of study methods 
and results, where necessary.
risk of bias in individual studies
For cohort or nested case–control studies, we adapted a tool 
published by the Cochrane Bias Methods Group.22 For cross-sec-
tional studies, we applied a previously used checklist7 23 (online 
supplementary file 2, online supplementary text S4).
summary measures
We defined incidence in cohort studies as the rate of new M. 
genitalium infections per 100 person-years of observation in 
individuals with a negative M. genitalium test, either at baseline 
or a negative test of cure following treatment of a prevalent 
infection. We defined persistence of M. genitalium infection in 
cohort studies as the proportion of study participants at each 
follow-up visit with a positive test result. We assessed concor-
dance of M. genitalium infection status in cross-sectional studies 
as the proportion of sexual partners of an infected index case 
that had a positive test result. We assessed the development of 
PID in cohort studies and calculated the odds ratio (OR) or risk 
ratio (RR) with 95% confidence intervals (CI) for PID in partici-
pants with and without M. genitalium infection at baseline.
synthesis of results
We used Stata (V.13.1; StataCorp, College Station, Texas, USA) 
for statistical analysis. We examined data about incidence, 
concordance and PID in forest plots. We stratified studies 
reporting incidence according to the level of development of the 
country in which the study was conducted, categorised as very 
high, high, medium and low using the United Nations Devel-
opment Programme Human Development Index (HDI),24 as we 
found differences between countries with higher or lower human 
development index in our linked review of M. genitalium preva-
lence.7 We stratified studies reporting concordance according to 
study design: studies can enrol couples irrespective of infection 
status and test all individuals for M. genitalium (referred to as 
partner studies), or can enrol an index case with M. genitalium 
and then test their partners (referred to as index case studies). We 
calculated the percentage (with 95% CI) concordance separately 
for women and men. We assessed the percentage of study vari-
ability between studies caused by heterogeneity other than that 
due to chance with the I2 statistic.25 Meta-analysis was conducted 
when deemed appropriate using fixed or random effects models. 
For estimates of incidence, we estimated a summary estimate of 
the incidence rate per 100 person-years of follow-up (with 95% 
CI). For concordance, we applied the Freeman-Tukey arcsine 
transformation to the proportions before meta-analysis and back 
transformed the summary estimate and its 95% CI.
The data about persistence of M. genitalium are presented 
graphically (Excel:mac 2008, V.12.3.6; Microsoft Corporation, 
Redmond, Washington, USA) without statistical analysis because 
we anticipated that the results would be too heterogeneous to 
combine.16 We conducted a subgroup analysis, using a test of 
interaction, of differences in concordance by study design.
risk of bias across studies
We did not test for small study biases with funnel plots because 
of the small number of included studies.
resulTs
We identified 4634 records and, after exclusion of duplicates 
and articles published before 1991, we screened 3820 records. 
We included 18 studies, some of which reported on more than 
one review question (table 1, online supplementary file 2, 
figure S1, table S1). Six studies reported on incidence,5 26–30 five 
reported on persistence,5 26–28 31 10 reported on concordance 
between partners31–40 and three studies reported on develop-
ment of PID.5 41 42
Incidence
We included six studies (online supplementary table S2),5 26–30 
with a total of 4201 female participants at baseline and follow-up 
of 3461 person-years. Two studies were conducted in countries 
with a very high HDI, with students (Great Britain 2)5 and with 
attendees of primary healthcare clinics (Australia 3).29 All three 
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Table 1 Included studies (n=18), ordered according to outcomes reported
study identifier study population study design review topics
Great Britain 25 Female students aged ≤27 years; universities and further 
education colleges, London, Great Britain
Cohort study Incidence, persistence, PID
Kenya 226 Female sex workers aged 18–35 years; Kariobangi Nairobi 
City Council, Nairobi, Kenya
Cohort study Incidence, persistence
Kenya 328 Female sex workers, median age 35.3 years; municipal STI 
clinic Mombasa, Kenya
Cohort study Incidence, persistence
Uganda 127 Female sex workers aged 18–40 years; red light areas within 
southern Kampala, Uganda
Cohort study Incidence, persistence
Australia 329 Young women aged 16–25 years; primary health clinics in 
Melbourne, Australia
Cohort study Incidence
USA/Kenya 130 High-risk women aged 18–45 years; research clinics in 
Mombasa and Nairobi, Kenya and Birmingham, USA
Cohort study Incidence
USA 731 Women aged 14–17 years and their partners; urban primary 
healthcare centres, Indianapolis, USA
Cohort study, cross-sectional sampling 
of couples
Persistence, concordance
Great Britain 834 Women and their partners; STI clinic, St. Mary's Hospital, 
London, Great Britain
Cross-sectional Concordance
Great Britain 933 Men and their partners; STI clinic, St. Mary's Hospital, London, 
Great Britain
Cross-sectional Concordance
Peru 135 Couples, men aged 19–60 years, women aged 18–55 years; 
two STI clinics, Lima, Peru
Cross-sectional Concordance
USA 832 Mexican-American and African-American women with non-
viral STI aged 14–45 years and their male partners; San 
Antonio Metropolitan Health District STI Clinic, USA
Cross-sectional Concordance
Sweden 236 Men aged 16–67 years and their partners; Örebrö University 
Hospital STI clinic, Sweden
Index cases and sexual partners Concordance
Sweden 537 Women aged 14–55 years and men aged 17–67 years and 
their partners; STI clinic, Falun, Sweden
Index cases and sexual partners Concordance
Sweden 1138 Women aged 15–54 years and their partners; Örebrö 
University Hospital STI clinic, Sweden
Index cases and sexual partners Concordance
Sweden 1239 Male patients with symptomatic recurrent and/or persistent 
urethritis aged 20–47 years and their partners; STI clinic, 
Karolinska Hospital, Stockholm, Sweden
Index cases and sexual partners Concordance
Australia 640 Partners of index cases with M. genitalium, median age of 
female heterosexual partners 26 years; male heterosexual 
partners 28 years; MSM partners 29 years; Melbourne Sexual 
Health Centre, Australia
Index cases and sexual partners Concordance
Sweden 1041 Women after medical or surgical termination of pregnancy 
aged 17–40 years; gynaecological outpatient department 
Malmö University Hospital, Sweden
Nested case–control study PID*
USA 642 Women after treatment and cure of PID aged 14–37 years; 
multiple clinical sites in the USA
Cohort study PID†
*Post-abortion upper genital tract infection.
†Endometritis considered as confirmed PID.
MSM, men who have sex with men; PID, pelvic inflammatory disease; STI, sexually transmitted infection.
studies from countries with a low HDI were conducted with 
female sex workers in (Uganda 1, Kenya 2 and Kenya 3).26–28 
Two of the four research clinics which enrolled participants for 
the USA/Kenya 1 study30 approached only female sex workers 
too. All women in the Uganda 1 study had a positive test for M. 
genitalium at baseline. Incidence was defined as a positive test 
result in women who had a preceding negative test result.27 All 
studies were at risk of bias (online supplementary table S3). All 
studies reported more than 20% loss to follow-up or did not 
report it.5 26–30 Only one (Great Britain 2) compared participants 
followed up until the end of the studies and participants lost to 
follow-up.5
Figure 1 shows that in countries with a very high HDI, the 
pooled estimate of incidence was 1.07 per 100 person-years 
(95% CI 0.61 to 1.53, 2 studies, I2 0%).5 29 The incidence rates 
in studies conducted among female sex workers were higher and 
too heterogeneous to combine (I2 96.7%).
Persistent detection of M. genitalium
We included five studies,5 26–28 31 with a total of 636 female partic-
ipants at baseline (online supplementary table S4). Three studies 
were conducted with female sex workers in Kenya and Uganda 
(Uganda 1, Kenya 2 and Kenya 3).26–28 The other two studies 
were conducted with adolescents enrolled from primary health-
care facilities (USA 7)31 and students from educational colleges 
(Great Britain 2).5 Duration of follow-up ranged from 12 weeks 
in USA 731 to 33 months in Kenya 2.26 Specific treatment for M. 
genitalium was not prescribed in any of the studies. All studies 
were at risk of bias in outcome assessment (online supplementary 
table S5). In Great Britain 2, women with a positive test result for 
C. trachomatis at baseline received antibiotics if they were in the 
intervention arm of the underlying randomised control trial but 
could have been treated before the 12-month follow-up.5 In all 
other studies, participants received either syndromic treatment 
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Figure 1 Incident M. genitalium infections per 100 person-years by human development index.24 Solid diamond and lines show the point estimate 
and 95% confidence intervals (CI) for each study. The diamond shows the point estimate and 95% CI of the summary estimate. The incidence 
estimates are plotted on a linear scale.
or treatment for diagnosed C. trachomatis, N. gonorrhoeae and/
or Trichomonas vaginalis at one-month to three-month intervals. 
Two studies (Great Britain 2, Kenya 2) distinguished persistent 
from re-infections with genotyping.5 26
Online supplementary figure S2 shows a rapid decrease 
in the proportion of women infected in four studies. Median 
persistence in the three studies of sex workers was one to three 
months. The Great Britain 2 study only assessed M. genitalium 
persistence at one subsequent time point at which 25.9% of 
participants were still infected after a median of 16 months.5 In 
USA 7, 31.3% of women remained positive at 8 weeks.31
Concordance
We included 10 cross-sectional studies,31–40 all of which were 
conducted in healthcare facilities (online supplementary table 
S6). Five partner studies enrolled a total of 869 couples irre-
spective of infection status31–35 and five index case studies36–40 
enrolled a total of 477 people with M. genitalium and 480 
sexual partners. Only the Australia 6 study enrolled MSM.40 
All studies were at risk of bias (online supplementary table 
S7).31–40 The response rate at baseline was only assessed in two 
studies in which it was below 70% (Great Britain 9 and Peru 
1).33 35
Figure 2 shows overall concordance rates of 39%–40% among 
male partners of women with M. genitalium and 40%–50% in 
female partners of infected men, with no marked differences 
according to study design (online supplementary table S8). 
Concordance among MSM (Australia 6) was 27% (95% CI 19% 
to 36%).40
Pelvic inflammatory disease
We included three prospective studies that examined the risk 
for PID in M. genitalium-infected compared with non-infected 
participants, with a total of 5139 participants at baseline (online 
supplementary table S9).5 41 42 The Great Britain 2 study enrolled 
female students in London,5 USA 6 studied women who had 
taken part in a randomised controlled trial, after treatment and 
cure of a first episode of PID42 and Sweden 10 was a nested case–
control study in women who had undergone medical or surgical 
termination of pregnancy.41 PID was diagnosed by endometrial 
biopsy in USA 6 and using clinical criteria in Great Britain 25 and 
Sweden 10.41 Follow-up was 6 weeks in Sweden 10,41 12 months 
in Great Britain 25 and 30 days in USA 6.42 All studies were at 
risk of bias (online supplementary table S10).5 41 42 None of the 
studies assessed whether factors that might be associated with 
progression to PID were similar between groups or compared 
individuals followed up with those lost to follow-up.
All studies found an association between M. genitalium and 
PID (figure 3). The summary RR for incident PID in the two 
cohort studies was 1.73 (95% CI 0.92 to 3.28, I2 0%). The OR 
for post-abortion upper genital tract infection was 6.29 (95% CI 
1.56 to 25.20).41
DIsCussIon
Main findings
In this systematic review, the incidence of M. genitalium was 1.07 
per 100 person-years (95% CI 0.61 to 1.53, I2 0%, 2 studies) in 
women in very highly developed countries. Median duration of 
persistence of M. genitalium was one to three months in four 
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Figure 2 Proportion of concordantly infected sexual partners of individuals with M. genitalium, by sex of index case and study design. Solid 
diamonds and lines show the point estimate and 95% confidence interval (CI) for each study. The diamond shows the point estimate and the 95% CI 
of the summary estimate. The proportions are plotted on a linear scale.
Figure 3 Risk of progression to upper genital tract infection in women with M. genitalium compared with women without M. genitalium. Solid 
diamonds and lines show the point estimate and 95% confidence interval (CI) for each study. The open diamond shows the point estimate and the 
95% CI of the summary estimate. The effect estimates are plotted on a logarithmic scale.
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Key messages
 ► There is debate about the need for widespread screening 
for Mycoplasma genitalium, but the natural history of 
this emerging sexually transmitted pathogen is poorly 
understood.
 ► M. genitalium incidence was 1.07 (95% CI 0.61 to 1.53) per 
100 person-years in women in highly developed countries, 
39%–50% of infected individuals had a heterosexual partner 
with M. genitalium and the risk ratio for progression to pelvic 
inflammatory disease was 1.73 (95% CI 0.92 to 3.28).
 ► The duration of untreated M. genitalium infection could not 
be determined from this review but is probably longer than 
persistent detection of M. genitalium, as measured in most 
cohort studies, in which inadvertent treatment cannot be 
ruled out.
 ► The results of this systematic review and other evidence 
sources show important differences in the epidemiology 
and dynamics of M. genitalium and Chlamydia trachomatis 
infection.
studies but 15 months in one study. In 10 studies measuring M. 
genitalium infection status in heterosexual couples, proportions 
of concordant results were 39% to 50%. In two prospective 
studies, the incidence of PID was higher in women with M. geni-
talium than those without (RR 1.73, 95% CI 0.92 to 3.28, I2 
0%).
strengths and limitations
A strength of our systematic review is the broad search strategy 
that covered differing topics, which makes it unlikely that we 
missed important relevant articles. In addition, selection of 
studies and extraction of data by independent reviewers reduces 
the risk of errors in data extraction. We assessed the risk of bias 
in all included studies. The relative importance of the domains 
of bias affect interpretation depend on the topic. For example, 
when measuring the duration of persistent detection, accurate 
assessment of the outcome, untreated infection is important, but 
most studies were at high risk of bias. The main limitations of the 
review findings result from the small number of studies overall 
and between study heterogeneity.
Interpretation of the findings
Incidence and persistent detection of M. genitalium: The find-
ings of this review do not allow an estimate of the duration 
of M. genitalium infectiousness. Estimates based on persistent 
detection in cohort studies are inconsistent (online supplemen-
tary figure S2, online supplementary table S4). Since duration of 
infection is related to prevalence (assessed in our linked review7) 
and incidence (figure 1), the findings can be compared with this 
alternative measure (Equation 1): duration of infection=preva-
lence÷incidence (1)
In this review, three studies estimated all three quantities 
(online supplementary table S11).5 26 28 In Great Britain 2,5 the 
duration of infection, both directly estimated and from Equation 
1, was more than one year. In Kenya 226 and Kenya 3,28 the dura-
tion was less than one year by both methods. In Uganda 1,27 the 
directly estimated duration was less than one year but prevalence 
was higher than incidence, so Equation 1 results in an estimated 
duration of more than one year. In two studies that measured 
incidence and prevalence but not persistent detection, duration 
of infection could only be obtained using Equation 1, with an 
estimate of more than one year for Australia 329 and less than 
one year for USA/Kenya 130 (online supplementary table S11). 
In all studies, women had opportunities for treatment with anti-
biotics with some activity against M. genitalium at frequencies 
of as little as a month. The duration of persistent detection was 
short in all studies that offered treatment every three months or 
more frequently. With likely inadvertent treatment and re-infec-
tion, these cohort studies probably did not measure the persis-
tence of untreated infection. Smieszek and White, who analysed 
the conflicting findings in the Great Britain 25 and Uganda 127 
studies using a mathematical model, favoured a longer duration 
of infection similar to the Great Britain 2 study.16 The uncer-
tainty about the duration of infectiousness of M. genitalium 
contrasts with C. trachomatis, for which the literature is exten-
sive and there is broad agreement that prevalence in general 
populations in high-income countries is around 3%–4%,23 inci-
dence is around 4%43 44 and average duration of infectiousness is 
slightly more than one year.14 45
M. genitalium concordance: The systematic review data 
suggest some possible differences between M. genitalium and 
C. trachomatis. Concordant M. genitalium status can be used 
to estimate the transmission probability of sexually transmitted 
pathogens.15 46 Cross-sectional studies of randomly sampled 
couples, irrespective of infection status, provide the least biased 
estimate.46 For this reason, we examined concordance separately 
in partner studies and in index case studies, but actually found 
similar estimates in both study designs. In cross-sectional studies, 
M. genitalium concordance was 39%–40%. In comparison, C. 
trachomatis concordance in a large cross-sectional study in the 
USA was 68% (95% CI 56% to 78%) for male partners and 70% 
(58% to 80%) for female partners.47 Findings from our system-
atic review of M. genitalium prevalence suggested that, while 
overall population prevalence of the two infections is similar, C. 
trachomatis positivity is concentrated in younger age groups.23
M. genitalium progression to PID: M. genitalium was associ-
ated with PID in prospective studies (RR 1.73, 95% CI 0.92 to 
3.28), with CIs that were compatible with both a small reduc-
tion and a substantial increase in risk. The point estimate was 
slightly lower than that found by Lis et al, but their inclusion 
of cross-sectional studies and studies of post-abortal PID in the 
same meta-analysis might have overestimated the association.3 
The increase in risk of PID following C. trachomatis is around 
1.8 to 2.8.48 49 Using data from the Great Britain 2 study and 
taking into account the low population prevalence of M. genita-
lium, Oakeshott et al estimated that the population attributable 
fraction of PID due to M. genitalium was about 4%.5
Implications for research and practice
This review adds to the evidence about the biology, dynamics 
and natural history of M. genitalium as a sexually transmitted 
pathogen. Additional empirical research is needed to provide 
robust data about the epidemiology of M. genitalium infection in 
men and to determine the persistence of untreated M. genitalium 
in studies in which inadvertent treatment can be excluded. In the 
context of evidence of high levels of macrolide resistance in M. 
genitalium,11 12 which does not affect C. trachomatis, measures 
for the management and control of these infections are likely to 
differ. Despite earlier speculation,5 the findings of this review, 
our linked review of prevalence7 and evidence about antimicro-
bial resistance show that M. genitalium is not the new chlamydia. 
The estimates from this systematic review can be used in math-
ematical modelling studies to investigate differences between 
the transmission dynamics of M. genitalium and C. trachomatis 
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and to investigate the potential benefits and harms of control 
interventions.
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